Our site in Brinny, Co. Cork is one of the region’s largest employers and has been a vibrant part of the pharmaceutical sector in Cork for over 35 years. With a successful legacy of developing and commercially supplying biotech products including some of MSD’s most successful treatments for Oncology, Hepatitis C and Rheumatoid Arthritis, Brinny is now specialising in the development and manufacture of innovative novel vaccines and testing of immuno-oncology medicines.
Our Ballydine site opened in 1976 and currently employs 500 highly skilled people. The site has API and Formulation facilities for the manufacture of commercial products and the development of new products. We invested €75 million between 2014 and 2017, furthering our commitment to this site. Work relating to 20 of MSD’s pipeline products is undertaken at this state-of-the-art research and commercialisation facility and we export products to approximately 25 countries around the world for further processing.
Our site in Carlow opened in 2008 as MSD’s first vaccines facility outside of the US. Carlow is the filling site for the liquid form of our immuno-oncology treatment for the global market and is a state-of-the-art vaccines and biologics facility. We employ over 400 staff and have invested significantly in the site since it opened. We are currently working on the construction of a second manufacturing facility in Carlow with the creation of an additional 170 jobs. The new facility will focus on the production of vaccines and biologics and there will also be an expansion of warehouse and laboratory services at the site. Recruitment for the new facility will commence immediately and it is intended that the new manufacturing operations will commence in 2023.
Red Oak North in Dublin is the base for our Animal Health and Human Health businesses as well as a number of global and national support services including Clinical Research, Medical Affairs, Regulatory Affairs, Sales, Policy & Communications and Marketing.
MSD Biotech, Dublin began construction in 2018 and has progressed at impressive rate since then. The site will play a pivotal role in the manufacture of MSD’s biologics-based medicines, including in the area of immuno-oncology, and will expand MSD’s current internal network of biologics drug substance manufacturing plants when full manufacturing operations begin in 2021.
The latest addition to the MSD, Ireland family is MSD Dunboyne which joined our network in September 2020. With a team of over 200, this site will be MSD’s first Biologics Drug Substance Single Use Commercialization Facility, playing an important role in helping us commercialise key medicines.